Skip to Content
Merck
  • Detection of NUCB2/nesfatin-1 in cerebrospinal fluid of multiple sclerosis patients.

Detection of NUCB2/nesfatin-1 in cerebrospinal fluid of multiple sclerosis patients.

Aging (2020-12-16)
Masaru Shimizu, Taizo Manome, Masumi Kumami, Kouzou Matsumura, Kazuaki Kanai, Kenju Shimomura, Yuko Maejima
ABSTRACT

NUCB2/nesfatin-1 was originally discovered as an anorexigenic peptide. However, recent studies revealed various additional functions including the regulation of inflammation. However, there are no studies that investigated the involvement of NUCB2/nesfatin-1 in neuroinflammatory diseases. Here, we aimed to investigate the involvement of NUCB2/nesfatin-1 in a representative neuroinflammatory disease, multiple sclerosis (MS). Cerebrospinal fluids (CSF) were collected from 24 MS patients and 10 control subjects and NUCB2/nesfatin-1, proinflammatory cytokines (TNF-α, IL-1β) and anti-inflammatory cytokines (IL-10, TGF-β) levels were measured by using ELISA assay. Also the expression of NUCB2/nesfatin-1 in the CSF of MS patient was investigated by western blot analysis. Expression of NUCB2/nesfatin-1 was confirmed in the CSF of the MS patient by western blot analysis. NUCB2/nesfatin-1 levels were significantly higher in the CSF of the MS patients. Among the measured cytokines, only IL-1β was lower in the CSF of the MS patients. We report for the first time increased NUCB2/nesfatin-1 levels in the CSF of MS patients.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-NUCB2 (N-terminal) antibody produced in rabbit, ~1.5 mg/mL, affinity isolated antibody, buffered aqueous solution